Medications used for ABPA include corticosteroids, amphotericin B, azole antifungals (isavuconazole, itraconazole, posaconazole, voriconazole), and a monoclonal antibody, omalizumab.Designing skin decontaminating materials with outstanding therapeutic effects, adhesiveness, and suitable mechanical property has great practical significance in radionuclide-contaminated skin wound healing. Here, a physically crosslinked hydrogel is constructed via hydrogen bonding of poly acrylamide, sodium alginate (SA), and the complexing agent diethylene triamine pentaacetic acid (DTPA). The physical and chemical properties of the poly(AAm-SA-DTPA) hydrogel (PASD) are detected according to established methods. The decontaminating property and skin wound healing of the PASD are investigated to confirm multi-functions of wound dressing. The physical and chemical properties results show that the synthesis of the PASD hydrogel is effective and that DTPA is present in the hydrogel. The hydrogel also shows great mechanical and swelling properties. In vitro tests find that PASD shows significant scavenging abilities for strontium and cerium. In vivo experiments show that the PASD hydrogel can remove radioactive strontium from the skin wounds of mice, and can effectively prevent the absorption of radioactive strontium through the skin wound. Furthermore, the PASD hydrogel can effectively promote the formation of granulation tissue in a radioactive contaminated wound. Taken together, the PASD hydrogels, which has good mechanical properties and radionuclides decontamination, is expected to be used as a dressing for radionuclide-contaminated skin wound healing.Data-independent-acquisition mass spectrometry (DIA-MS) is a state-of-the-art proteomic technique for high-throughput identification and quantification of peptides and proteins. Interpretation of DIA-MS data relies on the use of a spectral library, which is optimally created from data acquired from the same samples in data-dependent acquisition (DDA) mode. As DIA-MS quantification relies on the spectral libraries, having a high-quality, non-redundant, and comprehensive spectral library is essential. This article describes the major steps for creating a high-quality spectral library using a combination of multiple complementary search engines. We discuss appropriate strategies to control the false discovery rate for the final spectral library as a result of merging multiple searches. © 2021 The Authors Current Protocols © 2021 Wiley Periodicals LLC. Basic Protocol 1 Searching DDA-MS files with multiple search engines Basic Protocol 2 Merging results from multiple search engines Basic Protocol 3 Creating spectral libraries from merged results Alternate Protocol Using CLI for automating tasks Support Protocol Creating concatenated FASTA files.Sodium metal is regarded as one of the most prospective next-generation anodes material owing to its high theoretical capacity, low redox potential, low cost, and natural abundance. Its most notable problem is the dendrite growth during Na plating/striping, which causes not only the safety concern but also the generation of inactive Na. Here, it is demonstrated that 2D carbon nanosheets embedded by bismuth nanoparticles (NPs) (denoted as Bi⊂CNs) serve as a robust nucleation buffer layer to endow the sodium metal anodes (SMAs) with high Coulombic efficiencies (CEs) and dendrite-free deposition during long-term cycling. The embedded Bi nanoparticles significantly reduce the nucleation barrier through the "sodiophilic" Na-Bi alloy. Meanwhile, the carbon frameworks effectively circumvent the gradual failure of those Na-Bi nucleation sites. check details As a result, the metallic Na on the Bi⊂CNs nucleation layer is repeatedly plated/stripped for nearly 7700 h (1287 cycles) at 3 mA h cm-2 with an average CE of 99.92%. Moreover, the Na||Na symmetric cells with the Bi⊂CNs buffer layer are stably plated/stripped for 4000 h at 1 mA cm-2 and 1 mA h cm-2 . It is found that the cycling stability is closely related to the Na utilization of SMAs and current rate.The front cover artwork is provided by the group of Professor Keith Brown at Boston University. The image shows the magnetorheological fluid in a pressure-driven flow and highlights the length scales of the magnetic particles and highly anisotropic 2D sheets. Read the full text of the Article at 10.1002/cphc.202000948. As a highly heterogeneous disease, lung cancer has a multitude of cellular components and patterns of gene expression which are not dependent on a single mutation or signaling pathway. Thus, using combined drugs to treat lung cancer may be a practical strategy. The combined antitumor effects of HS-10296, a third-generation EGFR inhibitor targeting EGFR T790M mutation, with the multitargeted tyrosine kinase inhibitor (TKI) famitinib in non-small cell lung cancer (NSCLC) were evaluated by in vitro methods such as cell proliferation, apoptosis, angiogenesis assays, and in vivo animal efficacy studies. Famitinib strengthened the effects of HS-10296 on inhibiting proliferation and inducing apoptosis of NSCLC cells, possibly by synergistic inhibition of AKT and ERK phosphorylation. Meanwhile, HS-10296 significantly potentiated the effects of famitinib on inhibiting the proliferation and migration of HUVEC, which may be through synergistic inhibition of ERK phosphorylation in HUVEC, suggesting that HS-10296 may improve the inhibition of angiogenesis by famitinib. Moreover, combination of HS-10296 and famitinib exerted synergistic antitumor activity in NCI-H1975 and PC-9 xenograft models, and this effect may be accomplished by synergistic inhibition of phosphorylation of AKT and ERK and tumor angiogenesis in tumor tissues. Collectively, our results indicate that HS-10296 and famitinib exhibit significant synergistic antitumor activity, suggesting that the third-generation EGFR inhibitor combined with VEGFR inhibitor provides a promising strategy in the treatment of EGFR-mutant NSCLC.Collectively, our results indicate that HS-10296 and famitinib exhibit significant synergistic antitumor activity, suggesting that the third-generation EGFR inhibitor combined with VEGFR inhibitor provides a promising strategy in the treatment of EGFR-mutant NSCLC.